Drugs / Ivuxolimab
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03636503 | Oct 2018 → Jul 2021 | follicular lymphoma | Dana-Farber Cancer Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02315066 | Apr 2015 → Nov 2020 | neoplasm | Pfizer | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT03390296 | Dec 2017 → Feb 2022 | acute myeloid leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT03217747 | Aug 2017 → Sep 2025 overdue | castration-resistant prostate carcinoma, metastatic carcinoma in the bone, metastatic prostate carcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02554812 | Nov 2015 → Mar 2023 | cancer of unknown primary site | Pfizer | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03971409 | Jul 2019 → Jan 2027 expected | female breast carcinoma, invasive breast carcinoma, triple-negative breast carcinoma | Laura Huppert, MD, BA | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03092856 | Jul 2017 → Dec 2026 expected | clear cell renal carcinoma | University of Southern California | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05059522 | Sep 2021 → Dec 2026 expected | non-small cell lung carcinoma, ovarian cancer, urothelial carcinoma | Pfizer | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2016-09-28 | Pfizer | Results Pfizer to Showcase Progress of Broad-Based Oncology Portfolio at European Society for Medical Oncology (ESMO) 2016 Congress pfizer.com ↗
These preliminary results evaluating 25 patients suggest that PF-04518600 is tolerated up to 3 mg/kg and showed early anti-tumor activity. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2016-09-28 | Pfizer | Pfizer to Showcase Progress of Broad-Based Oncology Portfolio at European Society for Medical Oncology (ESMO) 2016 Congress pfizer.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ivuxolimab | “Ivuxolimab (PF-04518600) and utomilumab (PF-05082566) are humanized agonistic IgG2 monoclonal antibodies against OX40 and 4-1BB, respectively.” PMID 36302562 ↗ Oct 2022 |
| Known as | Anti-ox40 antibody pf-04518600 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297883 ↗ |
| Known as | PF-04518600 | “Ivuxolimab (PF-04518600) and utomilumab (PF-05082566) are humanized agonistic IgG2 monoclonal antibodies against OX40 and 4-1BB, respectively.” PMID 36302562 ↗ Oct 2022 |
| Known as | PF-8600 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297883 ↗ |
| Action | Activate | “OX40 agonist mAb” NCT02554812 ↗ |
| Modality | Monoclonal antibody | “Ivuxolimab (PF-04518600) and utomilumab (PF-05082566) are humanized agonistic IgG2 monoclonal antibodies against OX40 and 4-1BB, respectively.” PMID 36302562 ↗ Oct 2022 |
| Route | Intravenous | “anti-OX40 antibody PF-04518600 intravenously (IV) over 60 minutes” NCT03092856 ↗ |
| Target | TNFRSF4 | “OX40 agonist monoclonal antibody (mAb)” NCT03390296 ↗ |